James Gordon
Stock Analyst at JP Morgan
(2.82)
# 1,755
Out of 4,869 analysts
8
Total ratings
80%
Success rate
17.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Gordon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRFS Grifols | Maintains: Neutral | $7.6 → $10 | $8.77 | +17.45% | 1 | Jun 17, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $640 → $670 | $542.15 | +23.58% | 5 | Nov 4, 2024 | |
| GMAB Genmab | Downgrades: Neutral | n/a | $21.16 | - | 1 | Aug 20, 2024 | |
| FGEN FibroGen | Upgrades: Neutral | n/a | $5.75 | - | 1 | Apr 7, 2021 |
Grifols
Jun 17, 2025
Maintains: Neutral
Price Target: $7.6 → $10
Current: $8.77
Upside: +17.45%
argenx SE
Nov 4, 2024
Maintains: Overweight
Price Target: $640 → $670
Current: $542.15
Upside: +23.58%
Genmab
Aug 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $21.16
Upside: -
FibroGen
Apr 7, 2021
Upgrades: Neutral
Price Target: n/a
Current: $5.75
Upside: -